Emerging Treatments High-Risk BCG-Unresponsive NMIBC setting

EP: 1.Overview of Non-Muscle Invasive Bladder Cancer (NMIBC)

EP: 2.Appropriate Risk Stratification Intermediate and high-risk Risk Classification

EP: 3.Adapting Urology Practices in the Face of BCG Shortages

EP: 4.Initial Treatment Selection for NMIBC in the Era of BCG Shortage

EP: 5.Strategies for the Management of Recurrent Low-Grade Bladder Tumors

EP: 6.Navigating Treatment Options for Elderly Patients with High-Risk NMIBC

EP: 7.Investigational Novel Strategies in High-Risk BCG-Unresponsive NMIBC

EP: 8.Review of Cretostimogene Grenadenorepvec (CG) Clinical Trials in High-risk BCG-unresponsive NMIBC

Now Viewing

EP: 9.Emerging Treatments High-Risk BCG-Unresponsive NMIBC setting

EP: 10.Treatment Strategies for BCG-Unresponsive NMIBC

EP: 11.Novel Approaches and Recent Trial Updates in Intermediate-risk NMIBC

EP: 12.Forward Looking NMIBC Treatment Advancements and Needs in 2024

This is a synopsis of the Viewpoints video series featuring moderator, Sam S. Chang, MD, MBA, from Vanderbilt University School of Medicine, and panelists Gary Steinberg, MD, FACS, from Rush University Medical Center, Mark Tyson, MD, of Mayo Clinic Phoenix, Roger Li, MD, from Moffitt Cancer Center, and Sandip M. Prasad, MD, MPhil, of Morristown Medical Center.

Episode 9 sheds light on innovative treatments and clinical trials for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). The panel of experts delves into a variety of approaches, including oncolytic immunotherapy, gene therapy, systemic immuno-oncology (IO) agents, antibody-drug conjugates (ADCs), and cytokine therapies. The discussion emphasizes the importance of personalized dosing regimens tailored to individual immune responses and underscores the significance of assessing longer-term efficacy beyond initial three-month response rates. Dr. Gary Steinberg highlights the multifaceted approach in treating NMIBC, mentioning oncolytic immunotherapy and gene therapy, including adstiladrin (nadofaragene firadenovec). He references trials involving single-agent systemic IO agents and ADCs, such intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC). Another notable mention is cytokine therapy with N-803, an immune cell–activating interleukin-15 (IL-15) superagonist combined with BCG, and EG-70 DNA delivery system delivering both IL-12 and activators of the innate immune receptor RIG-I to stimulate the immune system directly intravesically. The discussion also touches on dosing regimens (eg, EG 70 schedule of 800 micrograms administered at specific intervals over a 12-week period). Experts agree on the need to understand and assess individual patient immune responses to develop more intelligent dosing strategies. They point out that the immune system's response can vary, suggesting that complete responses might be observed later than the standard three-month mark, possibly at six months or one year. The conversation also includes other exciting trials and investigational agents, highlighting an approach that potentially reduces the patient burden and aligns with the current trend towards more effective and less burdensome cancer treatments. The panelists draw parallels to the evolution of treatment in other cancers like prostate and kidney cancer, where the introduction of novel agents and adjuvant immunotherapies has significantly advanced care.

In summary, Episode 9 provides an extensive overview of emerging treatments in high-risk BCG-unresponsive NMIBC, highlighting the importance of personalized medicine, longer-term efficacy evaluations, and the potential of novel therapeutic agents and strategies in improving patient outcomes.

*Video synopsis is AI-generated and reviewed by Urology Times® editorial staff.